The Structure of the Adenosine Receptors. Implications for Drug Discovery

Advances in Pharmacology

Volumn 61, Issue , 2011, Pages 1-40

  Lane, J Robert ^a,c   Jaakola, Veli Pekka ^b   IJzerman, Adriaan P ^c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF OULU   (Finland)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Adenosine receptors; Crystal structure; G protein coupled receptors; Ligand selectivity; Molecular modeling; Virtual ligand screening

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CHEMOKINE RECEPTOR CXCR4; G PROTEIN COUPLED RECEPTOR; MEMBRANE PROTEIN; RHODOPSIN; WATER;

BINDING AFFINITY; BINDING SITE; BOOK; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; COMPUTER MODEL; COVALENT BOND; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; CYTOPLASM; DRUG DEVELOPMENT; GLYCOSYLATION; HUMAN; HYDROGEN BOND; LIGAND BINDING; MUTAGENESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RECEPTOR DOWN REGULATION; STRUCTURE ANALYSIS; THERMOSTABILITY;

EID: 79955948707     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385526-8.00001-1     Document Type: Chapter

References (112)

1. Alexandrov A.I., Mileni M., Chien E.Y., Hanson M.A., Stevens R.C. Microscale fluorescent thermal stability assay for membrane proteins. Structure 2008, 16(3):351-359.
2. Altenbach C., Kusnetzow A.K., Ernst O.P., Hofmann K.P., Hubbell W.L. High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(21):7439-7444.
3. Angel T.E., Chance M.R., Palczewski K. Conserved waters mediate structural and functional activation of family A (rhodopsin-like) G protein-coupled receptors. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(21):8555-8560.
4. Barth P., Schonbrun J., Baker D. Toward high-resolution prediction and design of transmembrane helical protein structures. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(40):15682-15687.
5. 2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. Journal of Medicinal Chemistry 2004, 47(15):3707-3709.
6. 2B receptor followed by growth selection in yeast. Identification of constitutively active and gain of function mutations. Molecular Pharmacogy 2004, 65(3):702-710.
7. Bokoch M.P., Zou Y., Rasmussen S.G.F., Liu C.W., Nygaard R., Rosenbaum D.M., et al. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 2010, 463(7277):108-112.
8. 2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. Journal of Medicinal Chemistry 2009, 52(13):3994-4006.
9. Burstein E.S., Spalding T.A., Brann M.R. The second intracellular loop of the M5 muscarinic receptor is the switch which enables G-protein coupling. The Journal of Biological Chemistry 1998, 273(38):24322-24327.
10. 2 receptor-receptor heteromerization: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. The Journal of Biological Chemistry 2003, 278(47):46741-46749.
11. 2A adenosine receptor ligands. Journal of Medicinal Chemistry 2010, 53(9):3748-3755.
12. Chang L.C., Spanjersberg R.F., von Frijtag Drabbe Kunzel J.K., Mulder-Krieger T., van den Hout G., Beukers M.W., et al. 2,4,6-Trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. Journal of Medicinal Chemistry 2004, 47(26):6529-6540.
13. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G.F., Thian F.S., Kobilka T.S., et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318(5854):1258-1265.
14. Colotta V., Lenzi O., Catarzi D., Varano F., Filacchioni G., Martini C., et al. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. Journal of Medicinal Chemistry 2009, 52(8):2407-2419.
15. 2A receptor ligands. Handbook of Experimental Pharmacology 2009, 193:59-98.
16. 1 receptors. Biochemical Pharmacology 1998, 56(11):1437-1445.
17. 1 adenosine receptor. Molecular Pharmacology 2001, 59(5):1187-1195.
18. 2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity. Drug Development Research 1999, 48:95-103.
19. 2 -adrenoceptor reconciles structural and biochemical observations. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(12):4689-4694.
20. 2A receptor heteromers: New targets for caffeine in the brain. Frontiers in Bioscience 2008, 13:2391-2399.
21. 2 receptor interactions: Implications for the function of G protein-coupled receptors. Current Pharmaceutical Design 2008, 14(15):1468-1474.
22. Fishman P., Bar-Yehuda S., Synowitz M., Powell J.D., Klotz K.N., Gessi S., et al. Adenosine receptors and cancer. Handbook of Experimental Pharmacology 2009, 193:399-441.
23. Fredholm B.B., Chen J.F., Masino S.A., Vaugeois J.M. Actions of adenosine at its receptors in the CNS: Insights from knockouts and drugs. Annual Review of Pharmacology and Toxicology 2005, 45:385-412.
24. Fredholm B.B., IJzerman A.P., Jacobson K.A., Klotz K.N., Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacological Reviews 2001, 53(4):527-552.
25. 2 heteromeric receptor complexes and their function. Journal of Molecular Neuroscience 2005, 26(2-3):209-220.
26. Gao Z.G., IJzerman A.P. Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions. Biochemical Pharmacology 2000, 60(5):669-676.
27. 3 adenosine receptor. The Journal of Biological Chemistry 2002, 277(21):19056-19063.
28. 2A adenosine receptors: Involvement of glu(13) and his(278) in ligand binding and sodium modulation. Biochemical Pharmacology 2000, 60(5):661-668.
29. 1 adenosine receptor: Enhanced proteolysis of palmitoylation-deficient mutant receptors. The Biochemical Journal 1999, 342(Pt. 2):387-395.
30. 1 adenosine receptor-G-protein complexes: Effects of receptor down-regulation and phosphorylation on coupling. The Biochemical Journal 1999, 338(Pt. 3):729-736.
31. 3 adenosine receptor: An enigmatic player in cell biology. Pharmacology & Therapeutics 2008, 117(1):123-140.
32. 2A receptor blockade increases extracellular dopamine release following L-DOPA administration in intact and dopamine-denervated rats. Neuropharmacology 2004, 47(3):414-426.
33. 2A receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum. Neurotoxicity Research 2009, 15(2):155-166.
34. Hanson M.A., Stevens R.C. Discovery of new GPCR biology: One receptor structure at a time. Structure 2009, 17(1):8-14.
35. 2B adenosine receptors in immunity and inflammation. Trends in Immunology 2009, 30(6):263-270.
36. Hernan M.A., Takkouche B., Caamano-Isorna F., Gestal-Otero J.J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Annals of Neurology 2002, 52(3):276-284.
37. Hert J., Irwin J.J., Laggner C., Keiser M.J., Shoichet B.K. Quantifying biogenic bias in screening libraries. Nature Chemical Biology 2009, 5(7):479-483.
38. 2A receptor. ACS Medicinal Chemistry Letters 2010, 1(4):160-164.
39. Holst B., Nygaard R., Valentin-Hansen L., Bach A., Engelstoft M.S., Petersen P.S., Frimurer T.M., Schwartz T.W. A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors. The Journal of Biological Chemistry 2010, 285(6):3973-3985.
40. Hornak V., Ahuja S., Eilers M., Goncalves J.A., Sheves M., Reeves P.J., et al. Light activation of rhodopsin: Insights from molecular dynamics simulations guided by solid-state NMR distance restraints. Journal of Molecular Biology 2010, 396(3):510-527.
41. 2A receptor. Critical involvement of Glu13 in agonist recognition. European Journal of Pharmacology 1996, 310(2-3):269-272.
42. 2A adenosine receptor crystallographic structure. Journal of Medicinal Chemistry 2009, 52(10):3284-3292.
43. Jaakola V.P., Griffith M.T., Hanson M.A., Cherezov V., Chien E.Y., Lane J.R., et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322(5905):1211-1217.
44. 2A receptor in a high-affinity antagonist-bound state: Implications for GPCR drug screening and design. Current Opinion in Structural Biology 2010, 20(4):401-414.
45. 2A adenosine receptor: Identification and characterization of essential amino acid residues. The Journal of Biological Chemistry 2010, 285(17):13032-13044.
46. Jacobson K.A., Gao Z.G. Adenosine receptors as therapeutic targets. Nature Reviews. Drug Discovery 2006, 5(3):247-264.
47. 2A adenosine receptor and its agonists. Chemistry & Biology 2005, 12(2):237-247.
48. 2A adenosine receptors and biogenic amine G protein-coupled receptors. Journal of Medicinal Chemistry 1997, 40(16):2588-2595.
49. 2A adenosine receptors are required for ligand recognition. Molecular Pharmaceutics 1996, 50(3):512-521.
50. 2B adenosine receptor ligands. Handbook of Experimental Pharmacology 2009, (193):99-122.
51. 2A receptor antagonists. Journal of Medicinal Chemistry 2010, 53(4):1799-1809.
52. Katritch V., Kufareva I., Abagyan R. Structure based prediction of subtype-selectivity for adenosine receptor antagonists. Neuropharmacology 2010, 60(1):108-115.
53. 2A receptor complex. Proteins 2010, 78(1):197-211.
54. Kawate T., Gouaux E. Fluorescence-detection size-exclusion chromatography for precrystallization screening of integral membrane proteins. Structure 2006, 14(4):673-681.
55. 2A agonists and antagonists. Journal of Medicinal Chemistry 2003, 46(23):4847-4859.
56. 2A adenosine receptor are required for ligand recognition. Molecular Pharmaceutics 1996, 49(4):683-691.
57. 2A adenosine receptor. The Journal of Biological Chemistry 1995, 270(23):13987-13997.
58. Klaasse E.C., IJzerman A.P., de Grip W.J., Beukers M.W. Internalization and desensitization of adenosine receptors. Purinergic Signaling 2008, 4(1):21-37.
59. 1 receptors. European Journal of Pharmacology 2005, 522(1-3):1-8.
60. Klabunde T., Hessler G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem 2002, 3(10):928-944.
61. Kobilka B., Schertler G.F.X. New G-protein-coupled receptor crystal structures: Insights and limitations. Trends in Pharmacological Sciences 2008, 29(2):79-83.
62. Kolb P., Rosenbaum D.M., Irwin J.J., Fung J.J., Kobilka B.K., Shoichet B.K. Structure-based discovery of β2-adrenoceptor ligands. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(16):6843-6848.
63. 5.42 in ligand binding to and activation of the β2-adrenoceptor. The Journal of Biological Chemistry 2000, 275(48):37779-37788.
64. 2A receptor. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(31):10744-10749.
65. 2A adenosine receptor antagonists. Journal of Medicinal Chemistry 2008, 51(15):4449-4455.
66. Martinelli A., Tuccinardi T. Molecular modeling of adenosine receptors: New results and trends. Medicinal Research Reviews 2008, 28(2):247-277.
67. Marti-Renom M.A., Stuart A.C., Fiser A., Sanchez R., Melo F., Sali A. Comparative protein structure modeling of genes and genomes. Annual Review of Biophysics and Biomolecular Structure 2000, 29:291-325.
68. Michino M., Abola E., Brooks C.L., Dixon J.S., Moult J., Stevens R.C. Community-wide assessment of GPCR structure modelling and ligand docking: GPCRDock 2008. Nature Reviews. Drug Discovery 2009, 8(6):455-463.
69. Mobarec J.C., Sanchez R., Filizola M. Modern homology modeling of G-protein coupled receptors: Which structural template to use?. Journal of Medicinal Chemistry 2009, 52(16):5207-5216.
70. Moro S., Gao Z.G., Jacobson K.A., Spalluto G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Medicinal Research Reviews 2006, 26(2):131-159.
71. Moult J., Fidelis K., Kryshtafovych A., Rost B., Hubbard T., Tramontano A. Critical assessment of methods of protein structure prediction-Round VII. Proteins 2007, 69(Suppl. 8):3-9.
72. Mustafa S.J., Morrison R.R., Teng B., Pelleg A. Adenosine receptors and the heart: Role in regulation of coronary blood flow and cardiac electrophysiology. Handbook of Experimental Pharmacology 2009, 193:161-188.
73. 2 receptors. The Journal of Biological Chemistry 2009, 284(41):28058-28068.
74. Nygaard R., Frimurer T.M., Holst B., Rosenkilde M.M., Schwartz T.W. Ligand binding and micro-switches in 7TM receptor structures. Trends in Pharmacological Sciences 2009, 30(5):249-259.
75. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001, 414(6866):916-920.
76. 1 adenosine receptor. Studies on the ligand binding site by site-directed mutagenesis. The Journal of Biological Chemistry 1992, 267(15):10764-10770.
77. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289(5480):739-745.
78. 3 adenosine receptor. Evidence for a G-protein-coupled receptor kinase-mediated mechanism. The Journal of Biological Chemistry 1995, 270(49):29607-29613.
79. 3 adenosine receptor. The Journal of Biological Chemistry 1996, 271(25):15272-15278.
80. 2A adenosine receptor phosphorylation by protein kinase C activation: Evidence for regulation by multiple protein kinase C isoforms. Biochemistry 1999, 38(45):14833-14842.
81. 3 adenosine receptor. Molecular Pharmacology 2000, 57(3):539-545.
82. Park J.H., Scheerer P., Hofmann K.P., Choe H.W., Ernst O.P. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 2008, 454(7201):183-187.
83. Piirainen H., Ashok Y., Nanekar R.T., Jaakola V.P. Structural features of adenosine receptors: From crystal to function. Biochimica et Biophysica Acta 2010, (In press).
84. 2 -adrenergic G-protein-coupled receptor. Nature 2007, 450(7168):383-387.
85. 1 adenosine receptor. The Journal of Biological Chemistry 1999, 274(6):3617-3621.
86. 2 -adrenergic receptor function. Science 2007, 318(5854):1266-1273.
87. Rosenbaum D.M., Rasmussen S.G.F., Kobilka B.K. The structure and function of G-protein-coupled receptors. Nature 2009, 459(7245):356-363.
88. 2A receptor antagonist for the potential treatment of parkinsonism and other disorders. IDrugs 2010, 13(10):723-731.
89. Schapira A.H.V., Bezard E., Brotchie J., Calon F., Collingridge G.L., Ferger B., et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nature Reviews. Drug Discovery 2006, 5(10):845-854.
90. Scheerer P., Heck M., Goede A., Park J.H., Choe H.W., Ernst O.P., et al. Structural and kinetic modeling of an activating helix switch in the rhodopsin-transducin interface. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(26):10660-10665.
91. Scheerer P., Park J.H., Hildebrand P.W., Kim Y.J., Krauss N., Choe H.W., et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008, 455(7212):497-502.
92. 1 adenosine receptor. Biochemical Pharmacology 2000, 60(11):1647-1654.
93. Schwartz T.W., Frimurer T.M., Holst B., Rosenkilde M.M., Elling C.E. Molecular mechanism of 7TM receptor activation-a global toggle switch model. Annual Review of Pharmacology and Toxicology 2006, 46:481-519.
94. Sebastiao A.M., Ribeiro J.A. Adenosine receptors and the central nervous system. Handbook of Experimental Pharmacology 2009, 193:471-534.
95. Sheikh S.P., Zvyaga T.A., Lichtarge O., Sakmar T.P., Bourne H.R. Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F. Nature 1996, 383(6598):347-350.
96. Shi L., Liapakis G., Xu R., Guarnieri F., Ballesteros J.A., Javitch J.A. β2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. The Journal of Biological Chemistry 2002, 277(43):40989-40996.
97. 2 adenosine receptors?. Trends in Immunology 2005, 26(6):299-304.
98. Stefanachi A., Nicolotti O., Leonetti F., Cellamare S., Campagna F., Loza M.I., et al. 1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: Design, synthesis, structure-affinity and structure-selectivity relationships. Bioorganic & Medicinal Chemistry 2008, 16(22):9780-9789.
99. Stone T.W., Ceruti S., Abbracchio M.P. Adenosine receptors and neurological disease: Neuroprotection and neurodegeneration. Handbook of Experimental Pharmacology 2009, 193:535-587.
100. Strader C.D., Candelore M.R., Hill W.S., Sigal I.S., Dixon R.A. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. The Journal of Biological Chemistry 1989, 264(23):13572-13578.
101. Strader C.D., Sigal I.S., Candelore M.R., Rands E., Hill W.S., Dixon R.A. Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. The Journal of Biological Chemistry 1988, 263(21):10267-10271.
102. Thomas G.S., Thompson R.C., Miyamoto M.I., Ip T.K., Rice D.L., Milikien D., et al. The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. Journal of Nuclear Cardiology 2009, 16(1):63-72.
103. 1 adenosine receptor mediates specific agonist binding. The Journal of Biological Chemistry 1994, 269(4):2373-2376.
104. van Galen P.J., Nissen P., van Wijngaarden I., IJzerman A.P., Soudijn W. 1H-imidazo[4,5-c]quinolin-4-amines: Novel non-xanthine adenosine antagonists. Journal of Medicinal Chemistry 1991, 34(3):1202-1206.
105. van Veldhoven J.P., Chang L.C., von Frijtag Drabbe Kunzel J.K., Mulder-Krieger T., Struensee-Link R., Beukers M.W., et al. A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines. Bioorganic & Medicinal Chemistry 2008, 16(6):2741-2752.
106. Vedadi M., Niesen F.H., Allali-Hassani A., Fedorov O.Y., Finerty P.J., Wasney G.A., et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(43):15835-15840.
107. 1 -adrenergic G-protein-coupled receptor. Nature 2008, 454(7203):486-491.
108. Warne T., Serrano-Vega M.J., Tate C.G., Schertler G.F. Development and crystallization of a minimal thermostabilised G protein-coupled receptor. Protein Expression and Purification 2009, 65(2):204-213.
109. Wilson C.N., Nadeem A., Spina D., Brown R., Page C.P., Mustafa S.J. Adenosine receptors and asthma. Handbook of Experimnetal Pharmacology 2009, (193):329-362.
110. Wu B., Chien E.Y., Mol C.D., Fenalti G., Liu W., Katritch V., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330:1066-1071.
111. 2 -adrenergic-based homology models through the docking studies. Journal of Computational Chemistry 2009, 30(1):14-32.
112. 2A adenosine receptor: A GPCR with unique features?. British Journal of Pharmacology 2008, 153(S1):S184-S190.